ArticleBlood2020
Phase 1 study of lenzilumab, a recombinant anti-human GM-CSF antibody, for chronic myelomonocytic leukemia.
Open access · bronzeAbstract readClinical Trial, Phase IMulticenter Study
In one paragraph
Article in Blood, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
4.7field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 53 citations in OpenAlex.
- Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial.The Lancet. Respiratory medicine · 2022Trial
- The Role of Inflammation in CMML Pathobiology and Progression.Current hematologic malignancy reports · 2025Review
- Chronic Myelomonocytic Leukemia Microenvironment in Disease Progression and Therapy: Focus on Stepwise Reconfiguring of Myeloid-Immune Cell Interactions Driving Immune Tolerance.Current hematologic malignancy reports · 2025Review
- Clinical management of CMML-State of the art.British journal of haematology · 2025Review
- Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a practical guide to diagnosis and management.Leukemia · 2025Review
- Tissue macrophages: origin, heterogenity, biological functions, diseases and therapeutic targets.Signal transduction and targeted therapy · 2025Review
- Anti-GM-CSF autoantibodies in myeloid leukemias.Best practice & research. Clinical haematology · 2025Review
- Chronic myelomonocytic leukemia: molecular pathogenesis and therapeutic innovations.Haematologica · 2025Review
- Clinical perception and novel insights of chronic myelomonocytic leukemia: a 10-year multi-center retrospective study.Frontiers in medicine · 2025Article
- Adverse drug reactions associated with COVID-19 management.Naunyn-Schmiedeberg's archives of pharmacology · 2024Review
- Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management.American journal of hematology · 2024Review
- Proposals for Clinical Trials in Chronic Myelomonocytic Leukemia.Current treatment options in oncology · 2023Review
- Definitions, Biology, and Current Therapeutic Landscape of Myelodysplastic/Myeloproliferative Neoplasms.Cancers · 2023Review
- Concurrent chronic myelomonocytic leukemia and gastric carcinoma: a case report and literature review.AME case reports · 2023Article
- How I diagnose and treat chronic myelomonocytic leukemia.Haematologica · 2022Article
- Human autoantibodies underlying infectious diseases.The Journal of experimental medicine · 2022Article
- Increasing recognition and emerging therapies argue for dedicated clinical trials in chronic myelomonocytic leukemia.Leukemia · 2021Review
- Autocrine GMCSF Signaling Contributes to Growth of HER2Cancer research · 2021Article
- Examining disease boundaries: Genetics of myelodysplastic/myeloproliferative neoplasms.EJHaem · 2021Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 3 institutions in 1 country.
Mrinal M PatnaikDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN.
David A SallmanDepartment of Hematologic Malignancies, Moffitt Cancer Center, Tampa, FL.
Abhishek A MangaonkarDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN.
Rachel HeuerDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN.
Jeffery HirvelaDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN.
Darci ZblewskiDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN.
Aref Al-KaliDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN.
Moritz BinderDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN.
Maria E BalasisDepartment of Hematologic Malignancies, Moffitt Cancer Center, Tampa, FL.
Hannah NewmanDepartment of Hematologic Malignancies, Moffitt Cancer Center, Tampa, FL.
Christopher LetsonDepartment of Hematologic Malignancies, Moffitt Cancer Center, Tampa, FL.
Traci L KruerDepartment of Hematologic Malignancies, Moffitt Cancer Center, Tampa, FL.
Naseema GangatDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN.
Rami S KomrokjiDepartment of Hematologic Malignancies, Moffitt Cancer Center, Tampa, FL.
Ayalew TefferiDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN.
Adrian LoHumanigen Inc, Burlingame, CA; and.
Ted ShihBeiGene, San Mateo, CA.
Cameron DurrantHumanigen Inc, Burlingame, CA; and.
Alan F ListDepartment of Hematologic Malignancies, Moffitt Cancer Center, Tampa, FL.
Eric PadronDepartment of Hematologic Malignancies, Moffitt Cancer Center, Tampa, FL.
Mayo Clinic in Arizona · USMoffitt Cancer Center · USHumanigen (United States) · US
Funding
TRANSLATIONAL RESEARCHP30CA076292 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI KENNETH Lynn WRIGHT · 1998 to 2026
$93.5MDeveloping and credentialing patient-derived xenograft models to advance therapeutic approaches for chronic myelomonocytic leukemiaR37CA234021 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI PADRON, ERIC · 2019 to 2025
$3.4MNCI NIH HHS P30 CA076292NCI NIH HHS R37 CA234021
Abstract
PubMed holds no abstract for this paper.
Indexed as
AgedAged, 80 and overAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalChemotherapy, AdjuvantDose-Response Relationship, DrugDrug-Related Side Effects and Adverse ReactionsFemaleGranulocyte-Macrophage Colony-Stimulating FactorHumansLeukemia, Myelomonocytic, ChronicMaleMaximum Tolerated DoseMiddle AgedRecombinant ProteinsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalGranulocyte-Macrophage Colony-Stimulating FactorlenzilumabRecombinant Proteins
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.